Microalbuminuria: A neglected cardiovascular risk factor in non-diabetic individuals?

Current Pharmaceutical Design

Volumn 19, Issue 27, 2013, Pages 4964-4980

  Lioudaki, Eirini ^a,b   Florentin, Matilda ^a,c   Ganotakis, Emmanuel S ^b   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF CRETE   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cardiovascular risk; Diabetes; Hypertension; Kidney; Microalbuminuria

Indexed keywords

ALBUMIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DISEASE; LIPID ANALYSIS; MEDLINE; METABOLIC SYNDROME X; MICROALBUMINURIA; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTEMATIC REVIEW; URINARY EXCRETION; VASCULAR DISEASE;

ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; KIDNEY; METABOLIC SYNDROME X; RENAL INSUFFICIENCY; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84881334804     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319270019     Document Type: Article

References (224)

1. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care 2004; 27 Suppl 1: S79-83.
2. de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: Public health perspectives. J Am Soc Nephrol 2006; 17: 2120-6.
3. Minetti EE, Cozzi MG, Granata S, Guidi E. Accuracy of the urinary albumin titrator stick 'Micral-Test' in kidney-disease patients. Nephrol Dial Transplant 1997; 12: 78-80.
4. Jensen JS, Clausen P, Borch-Johnsen K, et al. Detecting microalbuminuria by urinary albumin/creatinine concentration ratio. Nephrol Dial Transplant 1997; 12 Suppl 2: 6-9.
5. Mogensen CE, Vestbo E, Poulsen PL, et al. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995; 18: 572-81.
6. Gould MM, Mohamed-Ali V, Goubet SA, et al. Microalbuminuria: associations with height and sex in non-diabetic subjects. BMJ 1993; 306(6872): 240-2.
7. Metcalf PA, Scragg RK, Dryson E. Associations between body morphology and microalbuminuria in healthy middle-aged European, Maori and Pacific Island New Zealanders. Int J Obes Relat Metab Disord 1997; 21: 203-10.
8. Young BA, Katon WJ, Von Korff M, et al. Racial and ethnic differences in microalbuminuria prevalence in a diabetes population: the pathways study. J Am Soc Nephrol 2005; 16: 219-28.
9. Baber U, Mann D, Shimbo D, et al. Combined role of reduced estimated glomerular filtration rate and microalbuminuria on the prevalence of peripheral arterial disease. Am J Cardiol 2009; 104: 1446-51.
10. Mlacak B, Jaksic Z, Vuletic S. Albuminuria, cardiovascular morbidity and mortality in diabetic and non-diabetic subjects in a rural general practice. Fam Pract 1999; 16: 580-5.
11. Mann JF, Yi QL, Gerstein HC. Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney Int Suppl 2004; 66 (suppl 92): S59-62.
12. Berrut G, Bouhanick B, Fabbri P, et al. Microalbuminuria as a predictor of a drop in glomerular filtration rate in subjects with non-insulin-dependent diabetes mellitus and hypertension. Clin Nephrol 1997; 48: 92-7.
13. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-60.
14. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003; 254: 45-66.
15. Eijkelkamp WB, Zhang Z, Brenner BM, et al. Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. J Hypertens 2007; 25: 871-6.
16. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-6.
17. Basi S, Fesler P, Mimran A, Lewis JB. Microalbuminuria in type 2 diabetes and hypertension: a marker, treatment target, or innocent bystander? Diabetes Care 2008; 31 Suppl 2: S194-201.
18. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32: 219-26.
19. Verdecchia P, Reboldi GP. Hypertension and microalbuminuria: the new detrimental duo. Blood Press 2004; 13: 198-211.
20. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69.
21. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988; 2(8610): 530-3.
22. Gould MM, Mohamed-Ali V, Goubet SA, et al. Associations of urinary albumin excretion rate with vascular disease in Europid nondiabetic subjects. J Diabetes Complications 1994; 8: 180-8.
23. Winocour PH, Harland JO, Millar JP, et al. Microalbuminuria and associated cardiovascular risk factors in the community. Atherosclerosis 1992; 93: 71-81.
24. Haffner SM, Stern MP, Gruber MK, et al. Microalbuminuria. Potential marker for increased cardiovascular risk factors in nondiabetic subjects? Arteriosclerosis 1990; 10: 727-31.
25. Jensen JS, Borch-Johnsen K, Feldt-Rasmussen B, et al. Urinary albumin excretion and history of acute myocardial infarction in a cross-sectional population study of 2,613 individuals. J Cardiovasc Risk 1997; 4: 121-5.
26. Hillege HL, Janssen WM, Bak AA, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519-26.
27. Diercks GF, van Boven AJ, Hillege HL, et al. Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of REnal and Vascular ENdstage Disease) study. Eur Heart J 2000; 21: 1922-7.
28. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-82.
29. van de Wal RM, Gansevoort RT, van der Harst P, et al. Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients. Hypertension 2006; 48: 870-6.
30. Gerstein HC, Mann JF, Pogue J, et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care 2000; 23 Suppl 2: B35-9.
31. Foster MC, Hwang SJ, Larson MG, et al. Cross-classification of microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes. Arch Intern Med 2007; 167: 1386-92.
32. Wu CK, Yang CY, Tsai CT, et al. Association of low glomerular filtration rate and albuminuria with peripheral arterial disease: The National Health and Nutrition Examination Survey, 1999-2004. Atherosclerosis 2010; 209: 230-4.
33. Hoseini VN, Rasouli M. Microalbuminuria correlates with the prevalence and severity of coronary artery disease in non-diabetic patients. Cardiol J 2009; 16: 142-5.
34. Yuyun MF, Khaw KT, Luben R, et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol 2004; 33: 189-98.
35. Yuyun MF, Khaw KT, Luben R, et al. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. Am J Epidemiol 2004; 159: 284-93.
36. Romundstad S, Holmen J, Kvenild K, et al. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. Am J Kidney Dis 2003; 42: 466-73.
37. Gorgels WJ, van der Graaf Y, Hjemdahl P, et al. Urinary excretions of high molecular weight beta-thromboglobulin and albumin are independently associated with coronary heart disease in women, a nested case-control study of middle-aged women in the Diagnostisch Onderzoek Mammacarcinoom (DOM) Cohort, Utrecht, Netherlands. Am J Epidemiol 1995; 142: 1157-64.
38. Roest M, Banga JD, Janssen WM, et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 2001; 103: 3057-61.
39. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990; 300(6720): 297-300.
40. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Eight to nine year mortality in known non-insulin dependent diabetics and controls. Kidney Int 1992; 41: 731-5.
41. Damsgaard EM, Froland A, Jorgensen OD, Morgensen CE. Prognostic value of urinary albumin excretion rate and other risk factors in elderly diabetic patients and non-diabetic control subjects surviving the first 5 years after assessment. Diabetologia 1993; 36: 1030-6.
42. Ljungman S, Wikstrand J, Hartford M, Berglund G. Urinary albumin excretion--a predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Am J Hypertens 1996; 9: 770-8.
43. Beamer NB, Coull BM, Clark WM, Wynn M. Microalbuminuria in ischemic stroke. Arch Neurol 1999; 56: 699-702.
44. Slowik A, Turaj W, Iskra T, et al. Microalbuminuria in nondiabetic patients with acute ischemic stroke: prevalence, clinical correlates, and prognostic significance. Cerebrovasc Dis 2002; 14: 15-21.
45. Gosling P, Hughes EA, Reynolds TM, Fox JP. Microalbuminuria is an early response following acute myocardial infarction. Eur Heart J 1991; 12: 508-13.
46. Taskiran M, Feldt-Rasmussen B, Jensen GB, Jensen JS. Urinary albumin excretion in hospitalized patients with acute myocardial infarction. Prevalence of microalbuminuria and correlation to left ventricle wall thickness. Scand Cardiovasc J 1998; 32: 163-6.
47. Berton G, Cordiano R, Mbaso S, et al. Prognostic significance of hypertension and albuminuria for early mortality after acute myocardial infarction. J Hypertens 1998; 16: 525-30.
48. Lekatsas I, Koulouris S, Triantafyllou K, et al. Prognostic significance of microalbuminuria in non-diabetic patients with acute myocardial infarction. Int J Cardiol 2006; 106: 218-23.
49. Berton G, Cordiano R, Palmieri R, et al. Microalbuminuria during acute myocardial infarction; a strong predictor for 1-year mortality. Eur Heart J 2001; 22: 1466-75.
50. Koulouris S, Lekatsas I, Karabinos I, et al. Microalbuminuria: a strong predictor of 3-year adverse prognosis in nondiabetic patients with acute myocardial infarction. Am Heart J 2005; 149: 840-5.
51. Berton G, Cordiano R, Mazzuco S, et al. Albumin excretion in acute myocardial infarction: a guide for long-term prognosis. Am Heart J 2008; 156: 760-8.
52. Diercks GF, Hillege HL, van Boven AJ, et al. Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes. J Am Coll Cardiol 2002; 40: 1401.
53. Beijers HJ, Ferreira I, Bravenboer B, et al. Microalbuminuria and cardiovascular autonomic dysfunction are independently associated with cardiovascular mortality: evidence for distinct pathways: the Hoorn Study. Diabetes Care 2009; 32: 1698-703.
54. Parving HH, Mogensen CE, Jensen HA, Evrin PE. Increased urinary albumin-excretion rate in benign essential hypertension. Lancet 1974; 1(7868): 1190-2.
55. Pontremoli R, Sofia A, Ravera M, et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. Microalbuminuria: A Genoa Investigation on Complications. Hypertension 1997; 30: 1135-43.
56. Horner D, Fliser D, Klimm HP, Ritz E. Albuminuria in normotensive and hypertensive individuals attending offices of general practitioners. J Hypertens 1996; 14: 655-60.
57. Agewall S, Persson B, Samuelsson O, et al. Microalbuminuria in treated hypertensive men at high risk of coronary disease. The Risk Factor Intervention Study Group. J Hypertens 1993; 11: 461-9.
58. Pedrinelli R, Dell'Omo G, Penno G, et al. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. Hypertension 2000; 35(1 Pt 1): 48-54.
59. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16: 1325-33.
60. Bramlage P, Pittrow D, Lehnert H, et al. Frequency of albuminuria in primary care: a cross-sectional study. Eur J Cardiovasc Prev Rehabil 2007; 14: 107-13.
61. Leoncini G, Ratto E, Viazzi F, et al. Global risk stratification in primary hypertension: the role of the kidney. J Hypertens 2008; 26: 427-32.
62. Martinez MA, Moreno A, Aguirre de Carcer A, et al. Frequency and determinants of microalbuminuria in mild hypertension: a primary-care-based study. J Hypertens 2001; 19: 319-26.
63. Bohm M, Thoenes M, Danchin N, et al. Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. J Hypertens 2007; 25: 2317-24.
64. Agewall S, Fagerberg B. Risk factors that predict development of microalbuminuria in treated hypertensive men. The Risk Factor Intervention Study Group. Angiology 1996; 47: 963-72.
65. Goetz FC, Jacobs DR, Jr., Chavers B, et al. Risk factors for kidney damage in the adult population of Wadena, Minnesota. A prospective study. Am J Epidemiol 1997; 145: 91-102.
66. Tsioufis CP, Lambrou SG, Stefanadis CI, et al. Microalbuminuria is associated with abnormal thoracic aortic mechanics in essential hypertension. Am J Cardiol 2000; 86: 797-801, A9.
67. Cirillo M, Stellato D, Laurenzi M, et al. Pulse pressure and isolated systolic hypertension: association with microalbuminuria. The GUBBIO Study Collaborative Research Group. Kidney Int 2000; 58: 1211-8.
68. Palatini P, Mormino P, Santonastaso M, et al. Target-organ damage in stage I hypertensive subjects with white coat and sustained hypertension: results from the HARVEST study. Hypertension 1998; 31: 57-63.
69. Hoegholm A, Bang LE, Kristensen KS, et al. Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension. Hypertension 1994; 24: 101-5.
70. Martinez MA, Garcia-Puig J, Martin JC, et al. Frequency and determinants of white coat hypertension in mild to moderate hypertension: a primary care-based study. Monitorizacion Ambulatoria de la Presion Arterial (MAPA)-Area 5 Working Group. Am J Hypertens 1999; 12: 251-9.
71. Hoegholm A, Kristensen KS, Bang LE, Nielsen JW. White coat hypertension and target organ involvement: the impact of different cut-off levels on albuminuria and left ventricular mass and geometry. J Hum Hypertens 1998; 12: 433-9.
72. Pierdomenico SD, Lapenna D, Guglielmi MD, et al. Target organ status and serum lipids in patients with white coat hypertension. Hypertension 1995; 26: 801-7.
73. Bianchi S, Bigazzi R, Baldari G, et al. Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens 1994; 7: 23-9.
74. Pedrinelli R. Microalbuminuria in Hypertension. Nephron 1996; 73: 499-505.
75. Turfaner N, Karter Y, Curgunlu A, et al. Blunted nocturnal fall of blood pressure in isolated clinical hypertension. Swiss Med Wkly 2009; 139: 251-5.
76. Jensen JS, Feldt-Rasmussen B, Strandgaard S, et al. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000; 35: 898-903.
77. Romundstad S, Holmen J, Hallan H, et al. Microalbuminuria and all-cause mortality in treated hypertensive individuals: does sex matter? The Nord-Trondelag Health Study (HUNT), Norway. Circulation 2003; 108: 2783-9.
78. Schrader J, Luders S, Kulschewski A, et al. Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*. J Hypertens 2006; 24: 541-8.
79. Wachtell K, Olsen MH, Dahlof B, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 2002; 20: 405-12.
80. Wachtell K, Palmieri V, Olsen MH, et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J 2002; 143: 319-26.
81. Agewall S, Wikstrand J, Ljungman S, et al. Does microalbuminuria predict cardiovascular events in nondiabetic men with treated hypertension? Risk Factor Intervention Study Group. Am J Hypertens 1995; 8(4 Pt 1): 337-42.
82. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
83. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.
84. Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, et al. Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals. J Hum Hypertens 1997; 11: 727-32.
85. Cotter J, Oliveira P, Cunha P, Polonia J. Risk factors for development of microalbuminuria in diabetic and nondiabetic normoalbuminuric hypertensives with high or very high cardiovascular risk-a twelve-month follow-up study. Nephron Clin Pract 2009; 113: c8-15.
86. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139: 901-6.
87. Olsen MH, Wachtell K, Bella JN, et al. Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy. J Hum Hypertens 2004; 18: 453-9.
88. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14: 223-8.
89. Burnier M, Zanchi A. Blockade of the renin-angiotensinaldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24: 11-25.
90. Barnett A. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. J Am Soc Nephrol 2006; 17(4 Suppl 2): S132-5.
91. Marre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004; 328(7438): 495.
92. Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000; 58: 762-9.
93. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
94. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253-9.
95. Parving HH, Andersen S, Jacobsen P, et al. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Semin Nephrol 2004; 24: 147-57.
96. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003; 26: 2268-74.
97. Rossing K, Schjoedt KJ, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68: 1190-8.
98. Redon J, Rovira E, Miralles A, et al. Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002; 39: 794-8.
99. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809-16.
100. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198-202.
101. Olsen MH, Wachtell K, Ibsen H, et al. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006; 24: 775-81.
102. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372(9638): 547-53.
103. Shionoiri H, Kosaka T, Kita E, et al. Comparison of long-term therapeutic effect of an ACE inhibitor, temocapril, with that of a diuretic on microalbuminuria in non-diabetic essential hypertension. Hypertens Res 2000; 23: 593-600.
104. Aranda P, Segura J, Ruilope LM, et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis 2005; 46: 1074-9.
105. Parhofer KG, Birkeland KI, Defronzo R, et al. Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND). Int J Clin Pract 2010; 64: 160-8.
106. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT. The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population. Br J Clin Pharmacol 2002; 53: 31-6.
107. Jorgensen L, Jenssen T, Johnsen SH, et al. Albuminuria as risk factor for initiation and progression of carotid atherosclerosis in non-diabetic persons: the Tromso Study. Eur Heart J 2007; 28: 363-9.
108. Mykkanen L, Zaccaro DJ, O'Leary DH, et al. Microalbuminuria and carotid artery intima-media thickness in nondiabetic and NIDDM subjects. The Insulin Resistance Atherosclerosis Study (IRAS). Stroke 1997; 28: 1710-6.
109. Agewall S, Bjorn F. Microalbuminuria and intima-media thickness of the carotid artery in clinically healthy men. Atherosclerosis 2002; 164: 161-6.
110. Agewall S, Wikstrand J, Ljungman S, Fagerberg B. Urinary albumin excretion is associated with the intima-media thickness of the carotid artery in hypertensive males with non-insulin-dependent diabetes mellitus. J Hypertens 1995; 13: 463-9.
111. Pedrinelli R, Dell'Omo G, Penno G, et al. Dissociation between microalbuminuria and common carotid thickness in essential hypertensive men. J Hum Hypertens 2000; 14: 831-5.
112. Furtner M, Kiechl S, Mair A, et al. Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. Eur Heart J 2005; 26: 279-87.
113. Afonso L, Hari P, Kondur A, et al. Usefulness of microalbuminuria in patients with the metabolic syndrome to predict subclinical atherosclerosis and cardiovascular disease outcomes. Am J Cardiol 2010; 106: 976-83.
114. Tsioufis C, Stefanadis C, Toutouza M, et al. Microalbuminuria is associated with unfavourable cardiac geometric adaptations in essential hypertensive subjects. J Hum Hypertens 2002; 16: 249-54.
115. Dell'omo G, Giorgi D, Di Bello V, et al. Blood pressure independent association of microalbuminuria and left ventricular hypertrophy in hypertensive men. J Intern Med 2003; 254: 76-84.
116. Post WS, Blumenthal RS, Weiss JL, et al. Spot urinary albumincreatinine ratio predicts left ventricular hypertrophy in young hypertensive African-American men. Am J Hypertens 2000; 13: 1168-72.
117. Ratto E, Leoncini G, Viazzi F, et al. Inappropriate left ventricular mass is associated with microalbuminuria independently of left ventricular hypertrophy in primary hypertension. J Hypertens 2008; 26: 345-50.
118. Celentano A, Palmieri V, Esposito ND, et al. Inappropriate left ventricular mass in normotensive and hypertensive patients. Am J Cardiol 2001; 87: 361-3, A10.
119. de Simone G, Kitzman DW, Palmieri V, et al. Association of inappropriate left ventricular mass with systolic and diastolic dysfunction: the HyperGEN study. Am J Hypertens 2004; 17: 828-33.
120. de Simone G, Verdecchia P, Pede S, et al. Prognosis of inappropriate left ventricular mass in hypertension: the MAVI Study. Hypertension 2002; 40: 470-6.
121. Kramer H, Jacobs DR, Jr., Bild D, et al. Urine albumin excretion and subclinical cardiovascular disease. The Multi-Ethnic Study of Atherosclerosis. Hypertension 2005; 46: 38-43.
122. Leoncini G, Sacchi G, Ravera M, et al. Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension. J Hum Hypertens 2002; 16: 399-404.
123. Campese VM, Bianchi S, Bigazzi R. Association between hyperlipidemia and microalbuminuria in essential hypertension. Kidney Int Suppl 1999; 71: S10-3.
124. Cirillo M, Senigalliesi L, Laurenzi M, et al. Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The Gubbio Population Study. Arch Intern Med 1998; 158: 1933-9.
125. Cowan BR, Young AA, Anderson C, et al. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]). Am J Cardiol 2009; 104: 1484-9.
126. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009; 54: 1084-91.
127. Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34: 55-68.
128. Kario K, Matsuo T, Kobayashi H, et al. Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria. Arterioscler Thromb Vasc Biol 1996; 16: 455-61.
129. Pedrinelli R, Giampietro O, Carmassi F, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344(8914): 14-8.
130. Cottone S, Vadala A, Mangano MT, et al. Endothelium-derived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives. Am J Hypertens 2000; 13: 172-6.
131. Clausen P, Feldt-Rasmussen B, Jensen G, Jensen JS. Endothelial haemostatic factors are associated with progression of urinary albumin excretion in clinically healthy subjects: a 4-year prospective study. Clin Sci (Lond) 1999; 97: 37-43.
132. Hermans MM, Henry R, Dekker JM, et al. Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn Study. J Am Soc Nephrol 2007; 18: 1942-52.
133. Mule G, Cottone S, Cusimano P, et al. The association of microalbuminuria with aortic stiffness is independent of C-reactive protein in essential hypertension. Am J Hypertens 2009; 22: 1041-7.
134. Amabile N, Guerin AP, Leroyer A, et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 2005; 16: 3381-8.
135. Kinlay S, Creager MA, Fukumoto M, et al. Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. Hypertension 2001; 38: 1049-53.
136. Stam F, van Guldener C, Becker A, et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J Am Soc Nephrol 2006; 17: 537-45.
137. Hermans MM, Henry RM, Dekker JM, et al. Albuminuria, but not estimated glomerular filtration rate, is associated with maladaptive arterial remodeling: the Hoorn Study. J Hypertens 2008; 26: 791-7.
138. Stehouwer CD, Henry RM, Dekker JM, et al. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction--the Hoorn Study. Kidney Int Suppl 2004; 66 (suppl 92): S42-4.
139. Mule G, Cottone S, Vadala A, et al. Relationship between albumin excretion rate and aortic stiffness in untreated essential hypertensive patients. J Intern Med 2004; 256: 22-9.
140. Kim BJ, Lee HA, Kim NH, et al. The association of albuminuria, arterial stiffness, and blood pressure status in nondiabetic, nonhypertensive individuals. J Hypertens 2011; 29: 2091-8.
141. Clausen P, Jensen JS, Jensen G, et al. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 2001; 103: 1869-74.
142. Diercks GF, Stroes ES, van Boven AJ, et al. Urinary albumin excretion is related to cardiovascular risk indicators, not to flowmediated vasodilation, in apparently healthy subjects. Atherosclerosis 2002; 163: 121-6.
143. Solbu MD, Jenssen TG, Eriksen BO, Toft I. Changes in insulin sensitivity, renal function, and markers of endothelial dysfunction in hypertension--the impact of microalbuminuria: a 13-year followup study. Metabolism 2009; 58: 408-15.
144. Groop L, Ekstrand A, Forsblom C, et al. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulindependent) diabetes mellitus. Diabetologia 1993; 36: 642-7.
145. Niskanen L, Laakso M. Insulin resistance is related to albuminuria in patients with type II (non-insulin-dependent) diabetes mellitus. Metabolism 1993; 42: 1541-5.
146. Nosadini R, Solini A, Velussi M, et al. Impaired insulin-induced glucose uptake by extrahepatic tissue is hallmark of NIDDM patients who have or will develop hypertension and microalbuminuria. Diabetes 1994; 43: 491-9.
147. Nosadini R, Cipollina MR, Solini A, et al. Close relationship between microalbuminuria and insulin resistance in essential hypertension and non-insulin dependent diabetes mellitus. J Am Soc Nephrol 1992; 3(4 Suppl): S56-63.
148. Yu Y, Suo L, Yu H, et al. Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria. Diabetes Res Clin Pract 2004; 65: 95-104.
149. De Cosmo S, Minenna A, Ludovico O, et al. Increased urinary albumin excretion, insulin resistance, and related cardiovascular risk factors in patients with type 2 diabetes: evidence of a sexspecific association. Diabetes Care 2005; 28: 910-5.
150. Forsblom CM, Eriksson JG, Ekstrand AV, et al. Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM. Diabetologia 1995; 38: 363-9.
151. Utsunomiya K, Takamatsu K, Fukuta I, et al. Association of urinary albumin excretion with insulin resistance in Japanese subjects: impact of gender difference on insulin resistance. Intern Med 2009; 48: 1621-7.
152. Verhave JC, Hillege HL, Burgerhof JG, et al. Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women. J Am Soc Nephrol 2003; 14: 1330-5.
153. Hoehner CM, Greenlund KJ, Rith-Najarian S, et al. Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol 2002; 13: 1626-34.
154. Mykkanen L, Zaccaro DJ, Wagenknecht LE, et al. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998; 47: 793-800.
155. Yilmaz Y, Alahdab YO, Yonal O, et al. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism 2010; 59: 1327-30.
156. Fujikawa R, Okubo M, Egusa G, Kohno N. Insulin resistance precedes the appearance of albuminuria in non-diabetic subjects: 6 years follow up study. Diabetes Res Clin Pract 2001; 53: 99-106.
157. Bianchi S, Bigazzi R, Valtriani C, et al. Elevated serum insulin levels in patients with essential hypertension and microalbuminuria. Hypertension 1994; 23(6 Pt 1): 681-7.
158. Redon J, Miralles A, Pascual JM, et al. Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension. J Hypertens 1997; 15: 79-86.
159. Bianchi S, Bigazzi R, Quinones Galvan A, et al. Insulin resistance in microalbuminuric hypertension. Sites and mechanisms. Hypertension 1995; 26: 789-95.
160. Yip JW, Jones C, Facchini F, et al. Insulin resistance in patients with essential hypertension can occur in the absence of microalbuminuria. Am J Hypertens 1996; 9(10 Pt 1): 959-63.
161. Pedrinelli R, Dell'Omo G, Giampietro O, et al. Dissociation between albuminuria and insulinaemia in hypertensive and atherosclerotic men. J Hum Hypertens 1999; 13: 129-34.
162. Toft I, Bonaa KH, Eikrem J, et al. Microalbuminuria in hypertension is not a determinant of insulin resistance. Kidney Int 2002; 61: 1445-52.
163. Ribstein J, du Cailar G, Mimran A. Combined renal effects of overweight and hypertension. Hypertension 1995; 26: 610-5.
164. Grandi AM, Santillo R, Zanzi P, et al. Microalbuminuria in nevertreated hypertensives: lack of relationship to hyperinsulinemia and genetic predisposition to hypertension. Am J Hypertens 2000; 13(4 Pt 1): 353-8.
165. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39: 167-74.
166. Falkner B, Hulman S, Kushner H. Insulin-stimulated glucose utilization and borderline hypertension in young adult blacks. Hypertension 1993; 22: 18-25.
167. Lin CY, Chen MF, Lin LY, et al. Insulin resistance is the major determinant for microalbuminuria in severe hypertriglyceridemia: implication for high-risk stratification. Intern Med 2008; 47: 1091-7.
168. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.
169. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
170. Ninomiya T, Kiyohara Y. Albuminuria and chronic kidney disease in association with the metabolic syndrome. J Cardiometab Syndr 2007; 2: 104-7.
171. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167-74.
172. Lin CC, Liu CS, Li TC, et al. Microalbuminuria and the metabolic syndrome and its components in the Chinese population. Eur J Clin Invest 2007; 37: 783-90.
173. Anvari MS, Boroumand MA, Pourgholi L, et al. Potential link of microalbuminuria with metabolic syndrome in patients undergoing coronary angiography. Arch Med Res 2009; 40: 399-405.
174. Hao Z, Konta T, Takasaki S, et al. The association between microalbuminuria and metabolic syndrome in the general population in Japan: the Takahata study. Intern Med 2007; 46: 341-6.
175. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 2003; 16(11 Pt 1): 952-8.
176. Liese AD, Hense HW, Doring A, et al. Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. J Hum Hypertens 2001; 15: 799-804.
177. Okpechi IG, Pascoe MD, Swanepoel CR, Rayner BL. Microalbuminuria and the metabolic syndrome in non-diabetic black Africans. Diab Vasc Dis Res 2007; 4: 365-7.
178. Thoenes M, Reil JC, Khan BV, et al. Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension. Vasc Health Risk Manag 2009; 5: 577-85.
179. Vyssoulis G, Karpanou E, Spanos P, et al. Urine albumin excretion, within normal range, reflects increasing prevalence of metabolic syndrome in patients with essential hypertension. J Clin Hypertens (Greenwich) 2010; 12: 597-602.
180. Bonnet F, Marre M, Halimi JM, et al. Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study. J Hypertens 2006; 24: 1157-63.
181. Olsen MH, Hansen TW, Christensen MK, et al. Impact of the metabolic syndrome on the predictive values of new risk markers in the general population. J Hum Hypertens 2008; 22: 634-40.
182. Pedrinelli R, Dell'Omo G, Penno G, et al. Microalbuminuria, a parameter independent of metabolic influences in hypertensive men. J Hypertens 2003; 2: 1163-9.
183. Solbu MD, Kronborg J, Jenssen TG, et al. Albuminuria, metabolic syndrome and the risk of mortality and cardiovascular events. Atherosclerosis 2009; 204: 503-8.
184. Klausen KP, Parving HH, Scharling H, Jensen JS. The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality. J Intern Med 2007; 262: 470-8.
185. Jassal SK, Langenberg C, von Muhlen D, et al. Usefulness of microalbuminuria versus the metabolic syndrome as a predictor of cardiovascular disease in women and men>40 years of age (from the Rancho Bernardo Study). Am J Cardiol 2008; 101: 1275-80.
186. Ko GT, So WY, Chan NN, et al. Prediction of cardiovascular and total mortality in Chinese type 2 diabetic patients by the WHO definition for the metabolic syndrome. Diabetes Obes Metab 2006; 8: 94-104.
187. Legato MJ, Gelzer A, Goland R, et al. Gender-specific care of the patient with diabetes: review and recommendations. Gend Med 2006; 3: 131-58.
188. Tanko LB, Bagger YZ, Qin G, et al. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation 2005; 111: 1883-90.
189. Ulmer H, Kelleher C, Diem G, Concin H. Why Eve is not Adam: prospective follow-up in 149650 women and men of cholesterol and other risk factors related to cardiovascular and all-cause mortality. J Womens Health (Larchmt) 2004; 13: 41-53.
190. Metcalf P, Baker J, Scott A, et al. Albuminuria in people at least 40 years old: effect of obesity, hypertension, and hyperlipidemia. Clin Chem. 1992; 38: 1802-8.
191. Klausen KP, Parving HH, Scharling H, Jensen JS. Microalbuminuria and obesity: impact on cardiovascular disease and mortality. Clin Endocrinol (Oxf) 2009; 71: 40-5.
192. Chang Y, Yoo T, Ryu S, et al. Abdominal obesity, systolic blood pressure, and microalbuminuria in normotensive and euglycemic Korean men. Int J Obes (Lond) 2006; 30: 800-4.
193. Kawar B, Bello AK, El Nahas AM. High prevalence of microalbuminuria in the overweight and obese population: data from a UK population screening programme. Nephron Clin Pract 2009; 112: c205-12.
194. Yesim TE, Ugurlu S, Caglar E, et al. Investigation of microalbuminuria in nondiabetic, normotensive obese women. Intern Med 2007; 46: 1963-5.
195. Nishijo M, Nakagawa H, Morikawa Y, et al. Microalbuminuria and hypertension in nondiabetic Japanese men. Am J Hypertens 1999; 12(1 Pt 1): 16-20.
196. Yagi S, Akaike M, Aihara KI, et al. Ezetimibe Ameliorates Metabolic Disorders and Microalbuminuria in Patients with Hypercholesterolemia. J Atheroscler Thromb 2010; 17: 173-80.
197. Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 2008; 200: 1-12.
198. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109(21 Suppl 1): II2-10.
199. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
200. Festa A, D'Agostino R, Howard G, et al. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 2000; 58: 1703-10.
201. Kshirsagar AV, Bomback AS, Bang H, et al. Association of Creactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). Am J Cardiol 2008; 101: 401-6.
202. Nakamura M, Onoda T, Itai K, et al. Association between serum Creactive protein levels and microalbuminuria: a population-based cross-sectional study in northern Iwate, Japan. Intern Med 2004; 43: 919-25.
203. Sabanayagam C, Lee J, Shankar A, et al. C-reactive protein and microalbuminuria in a multi-ethnic Asian population. Nephrol Dial Transplant. 2010; 25: 1167-72.
204. Stuveling EM, Bakker SJ, Hillege HL, et al. C-reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension 2004; 43: 791-6.
205. Tsioufis C, Dimitriadis K, Chatzis D, et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol 2005; 96: 946-51.
206. Tsioufis C, Dimitriadis K, Taxiarchou E, et al. Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. Am J Hypertens 2006; 19: 462-6.
207. Shetty GK, Economides PA, Horton ES, et al. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2450-7.
208. Pedrinelli R, Dell'Omo G, Di Bello V, et al. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol 2004; 24: 2414-9.
209. Perticone F, Maio R, Tripepi G, et al. Microalbuminuria, endothelial dysfunction and inflammation in primary hypertension. J Nephrol. 2007; 20 Suppl 12: S56-62.
210. Ardaillou R, Baud L. Tumor necrosis factor in glomerular injury. Contrib Nephrol 1996; 118: 59-67.
211. Batlle-Gualda E, Martinez AC, Guerra RA, Pascual E. Urinary albumin excretion in patients with systemic lupus erythematosus without renal disease. Ann Rheum Dis 1997; 56: 386-9.
212. Mahmud N, O'Connell MA, Stinson J, et al. Tumour necrosis factor-alpha and microalbuminuria in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995; 7: 215-9.
213. Gosling P, Sutcliffe AJ, Cooper MA, Jones AF. Burn and trauma associated proteinuria: the role of lipid peroxidation, renin and myoglobin. Ann Clin Biochem 1988; 25(Pt 1): 53-9.
214. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110: 32-5.
215. Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969-75.
216. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, et al. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1992-7.
217. Solomon SD, Lin J, Solomon CG, et al. Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation 2007; 116: 2687-93.
218. Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension 2005; 46: 33-7.
219. Klausen KP, Scharling H, Jensen JS. Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases. J Intern Med 2006; 260: 231-7.
220. Olsen MH, Hansen TW, Christensen MK, et al. New risk markers may change the HeartScore risk classification significantly in onefifth of the population. J Hum Hypertens 2009; 23: 105-12.
221. Wang TJ, Evans JC, Meigs JB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005; 111: 1370-6.
222. Mogensen CE, Chachati A, Christensen CK, et al. Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest 1985; 9: 85-95.
223. Karagiannis A, Mikhailidis DP, Tziomalos K, et al. Has the time come for a new definition of microalbuminuria? Curr Vasc Pharmacol 2008; 6: 81-3.
224. Danziger J. Importance of low-grade albuminuria. Mayo Clin Proc 2008; 83: 806-12.